



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

that empowers them to support people living with obesity, minimise unconscious bias, and prevent stigma. Although we welcome the recent UK Government focus on obesity, any action must be considered in the context of the experiences of people living with obesity, and an understanding of obesity as a complex chronic disease. Accordingly, we call on the UK Government to work with people living with obesity when developing guidance and COVID-19 recovery plans who are in frequent contact with the health-care system and have expertise on the barriers to accessing healthcare.<sup>6</sup>

SLB reports grants and personal fees from Novo Nordisk. KR is a trustee of the Association for the Study of Obesity. AAT reports grants, personal fees, and travel support from Sanofi, grants, personal fees and educational events grants from Novo Nordisk, travel support from Merck Sharp and Dohme, personal fees and travel support from Boehringer Ingelheim, personal fees from Lilly, AstraZeneca, Bristol-Myers Squibb, and Janssen, equipment and travel support from ResMed, equipment from Philips Respironics, Impeto Medical, and ANSAR Medical Technologies, grants and non-financial support from Napp, and equipment and support staff from Aptiva. All other authors declare no competing interests.

*S Le Brocq, K Clare, M Bryant, K Roberts, \*AA Tahrani, on behalf of the writing group from Obesity UK, the Obesity Empowerment Network, and the UK Association for the Study of Obesity*  
a.a.tahrani@bham.ac.uk

Obesity UK (SLB, KC); Obesity Empowerment Network (KC); Association for the Study of Obesity (MB); Clinical Trials Research Unit, University of Leeds, Leeds, UK (MB); Department of Health Sciences and the Hull York Medical School, University of York, York, UK (MB); School of Health and Related Research, University of Sheffield, Sheffield, UK (KR); and Institute of Metabolism and Systems Research, University of Birmingham, Birmingham B15 2TT, UK (AAT)

- 1 Caussy C, Pattou F, Wallet F, et al. Prevalence of obesity among adult inpatients with COVID-19 in France. *Lancet Diabetes Endocrinol* 2020; **8**: 562–64.
- 2 Public Health England. Disparities in the risks and outcomes of COVID-19. London: Public Health England, 2020 June.
- 3 Flint SW, Tahrani AA. COVID-19 and obesity—lack of clarity, guidance, and implications for care. *Lancet Diabetes Endocrinol* 2020; **8**: 474–75.
- 4 Wolfenden L, Ezzati M, Larijani B, Dietz W. The challenge for global health systems in preventing and managing obesity. *Obes Rev* 2019; **20**(suppl 2): 185–93.
- 5 Henderson WR, Griesdale DEG, Dominelli P, Ronco JJ. Does prone positioning improve oxygenation and reduce mortality in patients with acute respiratory distress syndrome? *Can Respir J* 2014; **21**: 213–15.
- 6 Albury C, Strain WD, Brocq SL, Logue J, Lloyd C, Tahrani A. The importance of language in engagement between health-care professionals and people living with obesity: a joint consensus statement. *Lancet Diabetes Endocrinol* 2020; **8**: 447–55.
- 7 Tomiyama AJ, Carr D, Granberg EM, et al. How and why weight stigma drives the obesity ‘epidemic’ and harms health. *BMC Med* 2018; **16**: 123.
- 8 Rubino F, Puhl RM, Cummings DE, et al. Joint international consensus statement for ending stigma of obesity. *Nat Med* 2020; **26**: 485–97.
- 9 Pila E, Sabiston CM, Brunet J, Castonguay AL, O’Loughlin J. Do body-related shame and guilt mediate the association between weight status and self-esteem? *J Health Psychol* 2015; **20**: 659–69.
- 10 Miller CT, Kaiser CR. A theoretical perspective on coping with stigma. *J Soc Issues* 2001; **57**: 73–92.



## COVID-19 and Cushing’s syndrome: recommendations for a special population with endogenous glucocorticoid excess

Published Online  
June 9, 2020  
[https://doi.org/10.1016/S2213-8587\(20\)30215-1](https://doi.org/10.1016/S2213-8587(20)30215-1)

Over the past few months, COVID-19, the pandemic disease caused by severe acute respiratory syndrome coronavirus 2, has been associated with a high rate of infection and lethality, especially in patients with comorbidities such as obesity, hypertension, diabetes, and immunodeficiency syndromes.<sup>1</sup>

These cardiometabolic and immune impairments are common comorbidities of Cushing’s syndrome, a condition characterised by excessive exposure to endogenous glucocorticoids. In patients with Cushing’s syndrome, the increased cardiovascular risk factors, amplified by the increased thromboembolic risk, and the increased susceptibility to severe infections, are the two leading causes of death.<sup>2</sup>

In healthy individuals in the early phase of infection, at the physiological level, glucocorticoids exert immunoenhancing effects, priming danger sensor and cytokine receptor expression, thereby sensitising the immune system to external agents.<sup>3</sup> However,

over time and with sustained high concentrations, the principal effects of glucocorticoids are to produce profound immunosuppression, with depression of innate and adaptive immune responses. Therefore, chronic excessive glucocorticoids might hamper the initial response to external agents and the consequent activation of adaptive responses. Subsequently, a decrease in the number of B-lymphocytes and T-lymphocytes, as well as a reduction in T-helper cell activation might favour opportunistic and intracellular infection. As a result, an increased risk of infection is seen, with an estimated prevalence of 21–51% in patients with Cushing’s syndrome.<sup>4</sup> Therefore, despite the absence of data on the effects of COVID-19 in patients with Cushing’s syndrome, one can make observations related to the compromised immune state in patients with Cushing’s syndrome and provide expert advice for patients with a current or past history of Cushing’s syndrome.

Fever is one of the hallmarks of severe infections and is present in up to around 90% of patients with COVID-19, in addition to cough and dyspnoea.<sup>1</sup> However, in active Cushing's syndrome, the low-grade chronic inflammation and the poor immune response might limit febrile response in the early phase of infection.<sup>2</sup> Conversely, different symptoms might be enhanced in patients with Cushing's syndrome; for instance, dyspnoea might occur because of a combination of cardiac insufficiency or weakness of respiratory muscles.<sup>2</sup> Therefore, during active Cushing's syndrome, physicians should seek different signs and symptoms when suspecting COVID-19, such as cough, together with dysgeusia, anosmia, and diarrhoea, and should be suspicious of any change in health status of their patients with Cushing's syndrome, rather than relying on fever and dyspnoea as typical features.

The clinical course of COVID-19 might also be difficult to predict in patients with active Cushing's syndrome. Generally, patients with COVID-19 and a history of obesity, hypertension, or diabetes have a more severe course, leading to increased morbidity and mortality.<sup>1</sup> Because these conditions are observed in most patients with active Cushing's syndrome,<sup>2</sup> these patients might be at an increased risk of severe course, with progression to acute respiratory distress syndrome (ARDS), when developing COVID-19. However, a key element in the development of ARDS during COVID-19 is the exaggerated cellular response induced by the cytokine increase, leading to massive alveolar-capillary wall damage and a decline in gas exchange.<sup>5</sup> Because patients with Cushing's syndrome might not mount a normal cytokine response,<sup>4</sup> these patients might paradoxically be less prone to develop severe ARDS with COVID-19. Moreover, Cushing's syndrome and severe COVID-19 are associated with hypercoagulability, such that patients with active Cushing's syndrome might present an increased risk of thromboembolism with COVID-19. Consequently, because low molecular weight heparin seems to be associated with lower mortality and disease severity in patients with COVID-19,<sup>6</sup> and because anticoagulation is also recommended in specific conditions in patients with active Cushing's syndrome,<sup>7</sup> this treatment is strongly advised in hospitalised patients with Cushing's syndrome who have COVID-19. Furthermore, patients with active Cushing's syndrome are at increased risk of prolonged duration of viral infections, as well as

**Panel: Risk factors and clinical suggestions for patients with Cushing's syndrome who have COVID-19**

**Reduction of febrile response and enhancement of dyspnoea**

Rely on different symptoms and signs suggestive of COVID-19, such as cough, dysgeusia, anosmia, and diarrhoea.

**Prolonged duration of viral infections and susceptibility to superimposed bacterial and fungal infections**

Consider prolonged antiviral and broad-spectrum antibiotic treatment.

**Impairment of glucose metabolism (negative prognostic factor)**

Optimise glycaemic control and select cortisol-lowering drugs that improve glucose metabolism.

**Hypertension (negative prognostic factor)**

Optimise blood pressure control and select cortisol-lowering drugs that improve blood pressure.

**Thrombosis diathesis (negative prognostic factor)**

Start antithrombotic prophylaxis, preferably with low-molecular-weight heparin treatment.

opportunistic infections, particularly atypical bacterial and invasive fungal infections, leading to sepsis and an increased mortality risk,<sup>2</sup> and COVID-19 patients are also at increased risk of secondary bacterial or fungal infections during hospitalisation.<sup>1</sup> Therefore, in cases of COVID-19 during active Cushing's syndrome, prolonged antiviral treatment and empirical prophylaxis with broad-spectrum antibiotics<sup>1,4</sup> should be considered, especially for hospitalised patients (panel).

Surgery represents the first-line treatment for all causes of Cushing's syndrome,<sup>8,9</sup> but during the pandemic a delay might be appropriate to reduce the hospital-associated risk of COVID-19, any post-surgical immunodepression, and thromboembolic risks.<sup>10</sup> Because immunosuppression and thromboembolic diathesis are common Cushing's syndrome features,<sup>2,4</sup> during the COVID-19 pandemic, cortisol-lowering medical therapy, including the oral drugs ketoconazole, metyrapone, and the novel osilodrostat, which are usually effective within hours or days, or the parenteral drug etomidate when immediate cortisol control is required, should be temporarily used.<sup>9</sup> Nevertheless, an expeditious definitive diagnosis and proper surgical resolution of hypercortisolism should be ensured in patients with malignant forms of Cushing's syndrome, not only to avoid disease progression risk but also for rapidly ameliorating hypercoagulability and immunosuppression;<sup>9</sup> however, if diagnostic procedures

cannot be easily secured or surgery cannot be done for limitations of hospital resources due to the pandemic, medical therapy should be preferred. Concomitantly, the optimisation of medical treatment for pre-existing comorbidities as well as the choice of cortisol-lowering drugs with potentially positive effects on obesity, hypertension, or diabetes are crucial to improve the eventual clinical course of COVID-19.

Once patients with Cushing's syndrome are in remission, the risk of infection is substantially decreased, but the comorbidities related to excess glucocorticoids might persist, including obesity, hypertension, and diabetes, together with thromboembolic diathesis.<sup>2</sup> Because these are features associated with an increased death risk in patients with COVID-19,<sup>1</sup> patients with Cushing's syndrome in remission should be considered a high-risk population and consequently adopt adequate self-protection strategies to minimise contagion risk.

In conclusion, COVID-19 might have specific clinical presentation, clinical course, and clinical complications in patients who also have Cushing's syndrome during the active hypercortisolaemic phase, and therefore careful monitoring and specific consideration should be given to this special, susceptible population. Moreover, the use of medical therapy as a bridge treatment while waiting for the pandemic to abate should be considered.

RP reports grants and personal fees from Novartis, Strongbridge, HRA Pharma, Ipsen, Shire, and Pfizer; grants from Corcept Therapeutics and IBSA Farmaceutici; and personal fees from Ferring and Italfarmaco. AMI reports non-financial support from Takeda and Ipsen; grants and non-financial support from Shire, Pfizer, and Corcept Therapeutics. BMKB reports grants from Novartis, Strongbridge, and Millendo; and personal fees from Novartis and Strongbridge.

AC reports grants and personal fees from Novartis, Ipsen, Shire, and Pfizer; personal fees from Italfarmaco; and grants from Lilly, Merck, and Novo Nordisk. All other authors declare no competing interests.

\*Rosario Pivonello, Rosario Ferrigno, Andrea M Isidori, Beverly M K Biller, Ashley B Grossman, Annamaria Colao  
rosario.pivonello@unina.it

Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università Federico II di Napoli, Naples 80131, Italy (RP, RF, AC); UNESCO Chair for Health Education and Sustainable Development, Federico II University, Naples, Italy (RP, AC); Department of Experimental Medicine, Sapienza University of Rome – Policlinico Umberto I – COVID Hospital, Rome, Italy (AMI); Neuroendocrine and Pituitary Tumor Clinical Center, Massachusetts General Hospital, Boston, MA, USA (BMKB); Centre for Endocrinology, Barts and the London School of Medicine, Queen Mary University of London, London, UK (ABG); and Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK (ABG)

- 1 Kakodkar P, Kaka N, Baig MN. A comprehensive literature review on the clinical presentation, and management of the pandemic coronavirus disease 2019 (COVID-19). *Cureus* 2020; **12**: e7560.
- 2 Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BMK, Colao A. Complications of Cushing's syndrome: state of the art. *Lancet Diabetes Endocrinol* 2016; **4**: 611–29.
- 3 Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. *Nat Rev Immunol* 2017; **17**: 233–47.
- 4 Hasenmajer V, Sbardella E, Sciarra F, Minnetti M, Isidori AM, Venneri MA. The immune system in Cushing's syndrome. *Trends Endocrinol Metab* 2020; published online May 6. DOI:10.1016/j.tem.2020.04.004.
- 5 Ye Q, Wang B, Mao J. The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19. *J Infect* 2020; **80**: 607–13.
- 6 Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *J Thromb Haemost* 2020; **18**: 1094–99.
- 7 Isidori AM, Minnetti M, Sbardella E, Graziadio C, Grossman AB. Mechanisms in endocrinology: the spectrum of haemostatic abnormalities in glucocorticoid excess and defect. *Eur J Endocrinol* 2015; **173**: R101–13.
- 8 Nieman LK, Biller BM, Findling JW, et al. Treatment of Cushing's syndrome: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab* 2015; **100**: 2807–31.
- 9 Pivonello R, De Leo M, Cozzolino A, Colao A. The treatment of Cushing's disease. *Endocr Rev* 2015; **36**: 385–486.
- 10 Newell-Price J, Nieman L, Reincke M, Tabarin A. Endocrinology in the time of COVID-19: management of Cushing's syndrome. *Eur J Endocrinol* 2020; published online April 1. DOI:10.1530/EJE-20-0352.



## Type 1 diabetes and fasting in Ramadan: time to rethink classification of risk?



In the past few decades, several advances have allowed people with type 1 diabetes to live near normal lives and participate in activities previously considered high risk. These advances include the provision of structured education, analogue insulins, technologies including constant subcutaneous insulin infusion (CSII), continuous glucose monitoring, and automated insulin delivery or artificial pancreas systems.<sup>1</sup> Despite these advances, there is a scarcity of detailed consensus guidance on type 1 diabetes and fasting in Ramadan. In this comment,

we present an up-to-date risk stratification tool to support people with type 1 diabetes considering fasting during Ramadan and health-care professionals.

Fasting during the month of Ramadan is a challenging situation given complete abstinence from food and water from dawn to dusk over consecutive days during an entire lunar month. Fasts in countries in the northern hemisphere can be 16–19 hours long and will remain over 16 hours for the next few years, providing a very small window to eat and drink during fasts.